AMERICAN SOCIETY FOR GASTROINTESTINAL ENDOSCOPY

Oppose Centers for Medicare and Medicaid Services' (CMS) proposal to implement an efficiency adjustment to Medicare Physician Fee Schedule payments. Support the Efficiency Adjustment Delay Act (H.R. 7520), which would stop the application of an efficiency adjustment until at least January 1, 2030. Oppose the CMS practice expense site differential proposal (no specific legislation) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation) Support the Improving Seniors Timely Access to Care Act (S. 1816, H.R. 3514) to codify CMS prior authorization regulations for MA plans and require greater transparency of prior authorization processes

Client expense: — · Firm income: $30,000

Matched citations: H.R. 3514

Oppose Centers for Medicare and Medicaid Services' (CMS) proposal to implement an efficiency adjustment to Medicare Physician Fee Schedule payments. Support the Efficiency Adjustment Delay Act (H.R. 7520), which would stop the application of an efficiency adjustment until at least January 1, 2030. Oppose the CMS practice expense site differential proposal (no specific legislation) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation) Support the Improving Seniors Timely Access to Care Act (S. 1816, H.R. 3514) to codify CMS prior authorization regulations for MA plans and require greater transparency of prior authorization processes

Client expense: — · Firm income: $30,000

Matched citations: H.R. 7520

Oppose Centers for Medicare and Medicaid Services' (CMS) proposal to implement an efficiency adjustment to Medicare Physician Fee Schedule payments. Support the Efficiency Adjustment Delay Act (H.R. 7520), which would stop the application of an efficiency adjustment until at least January 1, 2030. Oppose the CMS practice expense site differential proposal (no specific legislation) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation) Support the Improving Seniors Timely Access to Care Act (S. 1816, H.R. 3514) to codify CMS prior authorization regulations for MA plans and require greater transparency of prior authorization processes

Client expense: — · Firm income: $30,000

Matched citations: S. 1816

Oppose the Patients Deserve Price Tags Act (S. 2355), specifically Section 5.

Client expense: — · Firm income: $30,000

Matched citations: S. 2355

Medicare site neutral payment policy (No specific legislation) Prevent cuts to the Medicare Physician Fee Schedule, (S. 1640, H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025; H.R. 1 Impose restrictions on prior authorization practices used by Medicare Advantage plans (S. 1816, H.R. 3514) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 1

Medicare site neutral payment policy (No specific legislation) Prevent cuts to the Medicare Physician Fee Schedule, (S. 1640, H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025; H.R. 1 Impose restrictions on prior authorization practices used by Medicare Advantage plans (S. 1816, H.R. 3514) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 3514

Medicare site neutral payment policy (No specific legislation) Prevent cuts to the Medicare Physician Fee Schedule, (S. 1640, H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025; H.R. 1 Impose restrictions on prior authorization practices used by Medicare Advantage plans (S. 1816, H.R. 3514) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 879

Medicare site neutral payment policy (No specific legislation) Prevent cuts to the Medicare Physician Fee Schedule, (S. 1640, H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025; H.R. 1 Impose restrictions on prior authorization practices used by Medicare Advantage plans (S. 1816, H.R. 3514) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: S. 1640

Medicare site neutral payment policy (No specific legislation) Prevent cuts to the Medicare Physician Fee Schedule, (S. 1640, H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025; H.R. 1 Impose restrictions on prior authorization practices used by Medicare Advantage plans (S. 1816, H.R. 3514) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: S. 1816

Medicare site neutral payment policy (No specific legislation) Prevent cuts to the Medicare Physician Fee Schedule, H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 Impose restrictions on prior authorization practices used by Medicare Advantage plans (No specific legislation) Ask Congress to amend Section 1847A(c)(4) of the Social Security Act to extend the Secretary of Health and Human Services authority to use the wholesale acquisition cost (WAC) plus 3% as the reimbursement methodology for drugs under Medicare Part B until the Average Sales Price (ASP) reaches sustainable levels, as determined by the Secretary. This change will allow biosimilars administered in office settings to be reimbursed adequately so that physicians can afford to prescribe and administer biosimilars. (No specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 879

Support to Codify and enhance CMS regulations that advance interoperability and improve prior authorization in Medicare Advantage plans (H.R. 8702 / S. 4518) Support (H.R. 2474) that would provide Medicare payments for physician services with an annual inflationary update based on the Medicare Economic Index, similar to updates received by other health care providers. Revise budget neutrality requirements and triggers by supporting and passing the Provider Reimbursement Stability Act (H.R. 6371). Reduce administrative and financial burden of participation in the Merit-based Incentive Payment System. No specific legislation Improving patient access to biosimilars by closing the gap between the reimbursement rates and physician practice acquisition costs (no specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 2474

Support the Safe Step Act which provides exceptions to step therapy protocols used by health plans for consumers covered under ERISA (S 652, HR 2630)

Client expense: — · Firm income: $30,000

Matched citations: HR 2630

Support to Codify and enhance CMS regulations that advance interoperability and improve prior authorization in Medicare Advantage plans (H.R. 8702 / S. 4518) Support (H.R. 2474) that would provide Medicare payments for physician services with an annual inflationary update based on the Medicare Economic Index, similar to updates received by other health care providers. Revise budget neutrality requirements and triggers by supporting and passing the Provider Reimbursement Stability Act (H.R. 6371). Reduce administrative and financial burden of participation in the Merit-based Incentive Payment System. No specific legislation Improving patient access to biosimilars by closing the gap between the reimbursement rates and physician practice acquisition costs (no specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 6371

Support to Codify and enhance CMS regulations that advance interoperability and improve prior authorization in Medicare Advantage plans (H.R. 8702 / S. 4518) Support (H.R. 2474) that would provide Medicare payments for physician services with an annual inflationary update based on the Medicare Economic Index, similar to updates received by other health care providers. Revise budget neutrality requirements and triggers by supporting and passing the Provider Reimbursement Stability Act (H.R. 6371). Reduce administrative and financial burden of participation in the Merit-based Incentive Payment System. No specific legislation Improving patient access to biosimilars by closing the gap between the reimbursement rates and physician practice acquisition costs (no specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 8702

Support to Codify and enhance CMS regulations that advance interoperability and improve prior authorization in Medicare Advantage plans (H.R. 8702 / S. 4518) Support (H.R. 2474) that would provide Medicare payments for physician services with an annual inflationary update based on the Medicare Economic Index, similar to updates received by other health care providers. Revise budget neutrality requirements and triggers by supporting and passing the Provider Reimbursement Stability Act (H.R. 6371). Reduce administrative and financial burden of participation in the Merit-based Incentive Payment System. No specific legislation Improving patient access to biosimilars by closing the gap between the reimbursement rates and physician practice acquisition costs (no specific legislation)

Client expense: — · Firm income: $30,000

Matched citations: S. 4518

Support the Safe Step Act which provides exceptions to step therapy protocols used by health plans for consumers covered under ERISA (S 652, HR 2630)

Client expense: — · Firm income: $30,000

Matched citations: S 652

Support to Codify and enhance CMS regulations that advance interoperability and improve prior authorization in Medicare Advantage plans (H.R. 8702 / S. 4518) Support (H.R. 2474) that would provide Medicare payments for physician services with an annual inflationary update based on the Medicare Economic Index, similar to updates received by other health care providers. Revise budget neutrality requirements and triggers by supporting and passing the Provider Reimbursement Stability Act (H.R. 6371). Reduce administrative and financial burden of participation in the Merit-based Incentive Payment System. No specific legislation

Client expense: — · Firm income: $30,000

Matched citations: H.R. 2474

Support the Safe Step Act which provides exceptions to step therapy protocols used by health plans for consumers covered under ERISA (S 652, HR 2630)

Client expense: — · Firm income: $30,000

Matched citations: HR 2630

Support to Codify and enhance CMS regulations that advance interoperability and improve prior authorization in Medicare Advantage plans (H.R. 8702 / S. 4518) Support (H.R. 2474) that would provide Medicare payments for physician services with an annual inflationary update based on the Medicare Economic Index, similar to updates received by other health care providers. Revise budget neutrality requirements and triggers by supporting and passing the Provider Reimbursement Stability Act (H.R. 6371). Reduce administrative and financial burden of participation in the Merit-based Incentive Payment System. No specific legislation

Client expense: — · Firm income: $30,000

Matched citations: H.R. 6371

Support to Codify and enhance CMS regulations that advance interoperability and improve prior authorization in Medicare Advantage plans (H.R. 8702 / S. 4518) Support (H.R. 2474) that would provide Medicare payments for physician services with an annual inflationary update based on the Medicare Economic Index, similar to updates received by other health care providers. Revise budget neutrality requirements and triggers by supporting and passing the Provider Reimbursement Stability Act (H.R. 6371). Reduce administrative and financial burden of participation in the Merit-based Incentive Payment System. No specific legislation

Client expense: — · Firm income: $30,000

Matched citations: H.R. 8702

Support to Codify and enhance CMS regulations that advance interoperability and improve prior authorization in Medicare Advantage plans (H.R. 8702 / S. 4518) Support (H.R. 2474) that would provide Medicare payments for physician services with an annual inflationary update based on the Medicare Economic Index, similar to updates received by other health care providers. Revise budget neutrality requirements and triggers by supporting and passing the Provider Reimbursement Stability Act (H.R. 6371). Reduce administrative and financial burden of participation in the Merit-based Incentive Payment System. No specific legislation

Client expense: — · Firm income: $30,000

Matched citations: S. 4518